The role ofmarkers of low-grade inf lammation for the early time course of glycemic control, glucose disappearance rate, and B-Cell function in recently diagnosed type 1 and type 2 diabetes

Diabetes Care

Volumn 38, Issue 9, 2015, Pages 1758-1767

  Katharina, S Weber ^a,b   Nowotny, Bettina ^a,b   Strassburger, Klaus ^a,b   Pacini, Giovanni ^c   Mussig, Karsten ^a,b,d   Szendroedi, Julia ^a,b,d   Herder, Christian ^a,b   Roden, Michael ^a,b,d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c CNR   (Italy)

^d Department of Orthopedic Surgery   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH SENSITIVITY C REACTIVE PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; SOLUBLE E SELECTIN; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; UNCLASSIFIED DRUG; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLUCOSE DISAPPEARANCE RATE; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; BLOOD; CLINICAL TRIAL; METABOLIC CLEARANCE RATE; MIDDLE AGED; SECRETION (PROCESS);

ADULT; BIOMARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; E-SELECTIN; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN-SECRETING CELLS; INTERCELLULAR ADHESION MOLECULE-1; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 84962339649     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0169     Document Type: Article

References (38)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37(Suppl.1):S81-S90.
2. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011;91: 79-118.
3. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: An analysis from the Whitehall II study. Lancet 2009;373:2215- 2221.
4. Daneman D. Type 1 diabetes. Lancet 2006; 367:847-858.
5. Herder C, Roden M. Genetics of type 2 diabetes: pathophysiologic and clinical relevance. Eur J Clin Invest 2011;41:679-692.
6. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-846.
7. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS; DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 2010; 59:679-685.
8. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107.
9. Donath MY, Størling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 2008;29:334-350.
10. Festa A, D'Agostino R Jr., Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
11. Müller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002; 45:805-812.
12. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.
13. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study. Lancet 1999;353:1649-1652.
14. Herder C, Baumert J, Thorand B, et al. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia 2006;49:921-929.
15. Schölin A, Siegbahn A, Lind L, et al.; Diabetes Incidence Study in Sweden group. CRP and IL-6 concentrations are associated with poor glycemic control despite preserved beta-cell function during the first year after diagnosis of type 1 diabetes. Diabetes Metab Res Rev 2004; 20:205-210.
16. Menart-Houtermans B, Rütter R, Nowotny B, et al.; German Diabetes Study Group. Leukocyte profiles differ between type 1 and type 2 diabetes and are associated with metabolic phenotypes: results from the German Diabetes Study (GDS). Diabetes Care 2014;37:2326- 2333.
17. Ziegler D, Papanas N, Zhivov A, et al.; German Diabetes Study (GDS) Group. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes 2014;63: 2454-2463.
18. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977;26: 605-610.
19. Kahl S, Nowotny B, Piepel S, et al. Estimates of insulin sensitivity from the intravenous-glucosemodified- clamp test depend on suppression of lipolysis in type 2 diabetes: A randomised controlled trial. Diabetologia 2014;57:2094-2102.
20. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663-1672.
21. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003;17:305-322.
22. Pacini G, Tonolo G, Sambataro M, et al. Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulinmodified FSIGT. Am J Physiol 1998;274:E592- E599.
23. Paternoster R, Brame R. Using the correct statistical test for the equality of regression coefficients. Criminology 1998;36:859-866.
24. Altinova AE, Yetkin I, Akbay E, Bukan N, Arslan M. Serum IL-18 levels in patients with type 1 diabetes: relations to metabolic control and microvascular complications. Cytokine 2008;42:217-221.
25. Marfella R, Esposito K, Giunta R, et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 2000;101:2247-2251.
26. King DE, Mainous AG 3rd, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 2003;26:1535-1539.
27. Blüher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or type II diabetes. Diabetologia 2002;45:210-216.
28. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067- 2072.
29. Schnell O, Amann-Zalan I, Jelsovsky Z, et al. Changes in A1C levels are significantly associated with changes in levels of the cardiovascular risk biomarker hs-CRP: results from the SteP study. Diabetes Care 2013;36:2084-2089.
30. Ryysy L, Yki-Järvinen H. Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes. Diabetes Care 2001;24:549-554.
31. Schaumberg DA, Glynn RJ, Jenkins AJ, et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the Diabetes Control and Complications Trial. Circulation 2005;111:2446-2453.
32. Krebs M, Geiger M, Polak K, et al. Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man. Thromb Haemost 2003;90:422-428.
33. Rubin D, Claas S, Pfeuffer M, Nothnagel M, Foelsch UR, Schrezenmeir J. S-ICAM-1 and s-VCAM-1 in healthy men are strongly associated with traits of the metabolic syndrome, becoming evident in the postprandial response to a lipid-rich meal. Lipids Health Dis 2008;7:32.
34. Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y. High serum concentrations of soluble E-selectin in patients with impaired glucose tolerance with hyperinsulinemia. Atherosclerosis 2000;152:415-420.
35. Krebs M, Roden M. Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature. Diabetes Obes Metab 2005;7:621-632.
36. Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S. Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002;55:131-138.
37. Heliövaara MK, Teppo AM, Karonen SL, Tuominen JA, Ebeling P. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab 2005;7:729-736.
38. Pihoker C, Gilliam LK, Ellard S, et al.; SEARCH for Diabetes in Youth Study Group. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab 2013;98:4055- 4062.